Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Mitochondria in HIV and Aging (MITO+)

Authors not listed

University of Colorado, Denver · 2018

Abstract

Older adults with human immunodeficiency virus (HIV) and a long history of antiretroviral therapy have more mitochondrial dysfunction(definition)- the cells that help them make energy. This dysfunction in mitochondria may lead to symptoms of muscle fatigue, physical function impairment, and impaired exercise tolerance compared to HIV-uninfected controls of a similar age and body mass index (BMI). Furthermore, the investigators hypothesize that the older antiretroviral therapy (ART) of tenofovir disoproxil fumarate (TDF) is associated with greater impairment in mitochondrial function than the newer agent, tenofovir alafenamide (TAF).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-30 MST

Cite this

APA
Anonymous. (2018). Mitochondria in HIV and Aging (MITO+). <em>University of Colorado, Denver</em>. https://clinicaltrials.gov/study/NCT03489421
Vancouver
Anonymous. Mitochondria in HIV and Aging (MITO+). University of Colorado, Denver. 2018.
BibTeX
@misc{anon2018Mitoch, title = {Mitochondria in HIV and Aging (MITO+)}, author = {Anonymous}, journal = {University of Colorado, Denver}, year = {2018}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings